HIV Prevention and Alcohol (R01 Clinical Trials Optional)
ID: 357391Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357391

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at enhancing the HIV/AIDS prevention toolkit for populations impacted by alcohol use. This initiative seeks to integrate effective prevention and treatment interventions while developing and testing new strategies to address the behavioral and biological risks associated with HIV acquisition, particularly among high-risk groups such as men who have sex with men and transgender individuals. The anticipated funding for fiscal year 2025 is $2 million, with 2-4 awards expected, and applications must be submitted through Grants.gov by May 7, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-25-208-Full-Announcement.html
    PAS-25-208.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) through the National Institutes of Health, focusing on HIV Prevention and Alcohol. The purpose of this funding is to enhance the HIV/AIDS prevention toolkit specifically for populations affected by alcohol use, addressing behavioral and biological risks for HIV acquisition. The initiative aims to integrate effective prevention and treatment interventions and to develop and test new strategies, particularly in settings with higher incidence rates of HIV. Key research areas include PrEP utilization, treatment as prevention (TasP), integration of preventive strategies, and operational research. The funding opportunity encourages applications that address the needs of high-risk populations such as men who have sex with men, transgender individuals, and others affected by HIV/AIDS and alcohol misuse. The anticipated funding for fiscal year 2025 is $2 million, with 2-4 awards expected. Eligible applicants include universities, nonprofits, and governmental agencies. The application process involves adherence to specific guidelines and submission through the Grants.gov platform, with deadlines spread through 2025. This funding opportunity reflects a strategic effort by NIH to tackle health disparities related to HIV and alcohol in affected communities.
    Similar Opportunities
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at expanding HIV prevention strategies among populations affected by alcohol use. This initiative encourages research projects that explore the relationship between alcohol consumption and HIV risk behaviors, focusing on areas such as Pre-exposure Prophylaxis (PrEP) utilization, Treatment as Prevention (TasP), and the integration of preventive intervention strategies. The program is particularly significant for addressing health disparities among high-risk groups, including men who have sex with men (MSM) and women with high-risk partners. The NIH anticipates funding between $2 million for 2 to 4 awards, with a project period of up to five years. Interested applicants can submit their proposals through the NIH ASSIST system or Grants.gov, and should direct inquiries to grantsinfo@nih.gov. The application deadline is May 7, 2026.
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at expanding the HIV/AIDS prevention toolkit among populations impacted by alcohol use. This grant seeks to support research that integrates effective prevention and treatment interventions while addressing the behavioral and biological risks associated with alcohol consumption, particularly among high-risk groups. The initiative is crucial for informing the design of future clinical trials focused on HIV prevention, with an anticipated funding amount of approximately $1.5 million for 2-4 awards. Interested applicants, including higher education institutions and community organizations, must submit their proposals by September 7, 2025, and can find additional information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a Notice of Funding Opportunity (NOFO) titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)." This initiative aims to enhance the HIV prevention toolkit for populations affected by alcohol consumption, focusing on the integration of effective prevention and treatment interventions to reduce the incidence of new HIV infections. The program is particularly relevant for high-risk groups, including men who have sex with men, transgender individuals, and others impacted by alcohol-related HIV transmission, emphasizing the need for innovative strategies to address health disparities. The funding opportunity offers a total estimated program funding of $1.5 million for 2-4 awards, with individual project budgets capped at $450,000, and applications are due by May 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and should refer to the full announcement for detailed application guidelines.
    Notice of Intent to Publish a Funding Opportunity Announcement - Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Alcohol-HIV/AIDS Program Project, focusing on research related to comorbidities, coinfections, and complications associated with alcohol use and HIV/AIDS. This initiative aims to support innovative research that can lead to effective interventions to reduce HIV transmission and improve health outcomes for individuals living with HIV, particularly in the context of aging and alcohol-related health issues. The funding opportunity will utilize the NIH Program Project (P01) mechanism, with an estimated total program funding of $9 million and an award ceiling of $1 million for up to 8 expected awards. The NOFO is anticipated to be published in Summer 2025, with applications due in Fall 2025, and the estimated project start date is set for August 1, 2026.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at testing innovative care models that integrate HIV, addiction, and primary care services. This initiative seeks to address gaps in comprehensive health service delivery for individuals at heightened risk for HIV or living with HIV and substance use disorders, emphasizing the need for replicable and sustainable interventions. The program is critical for enhancing service delivery to vulnerable populations and aligns with national public health goals to combat the HIV epidemic in the United States. Interested applicants can apply for a share of the $2 million funding by March 20, 2025, and should direct inquiries to grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html for more details.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.